QUICK SEARCH:   [advanced] Author: Keyword(s):
Home     Help     Feedback     Subscriptions     Archive     Search     Table of Contents

doi: 10.1242/10.1242/jcs.00181

This Article Summary Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JCS Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lange, S. Articles by Ehler, E. Search for Related Content PubMed PubMed Citation Articles by Lange, S. Articles by Ehler, E. Social Bookmarking                         What's this?

Subcellular targeting of metabolic enzymes to titin in heart muscle may be mediated by DRAL/FHL-2

Stephan Lange^1,, Daniel Auerbach^1,*,, Patricia McLoughlin², Evelyne Perriard¹, Beat W. Schäfer², Jean-Claude Perriard^1, and Elisabeth Ehler¹

¹ Institute of Cell Biology, ETH Hönggerberg, 8093 Zurich, Switzerland
² Division of Clinical Chemistry and Biochemistry, Department of Pediatrics, University of Zurich, 8032 Zurich, Switzerland
^* Present address: Dualsystems Biotech AG, Winterthurerstrasse 190, 8057 Zürich, Switzerland

View larger version (30K): [in a new window]   Fig. 5. Mapping of the DRAL/FHL-2-binding site in the N2B region of titin. Five different GFP-tagged deletion constructs of the N2B region were assayed for their interaction with DRAL/FHL-2 in pull-down assays. (A) Schematic representation of the employed constructs. (B) Investigation of the interaction between deletion constructs of the N2B region and DRAL by a GST pull-down assay. Only constructs that contain the residues between 3749 and 4019 of the unique sequence 3 are able to bind to DRAL/FHL-2-GST. The putative DRAL/FHL-2-binding site is indicated by a dotted line in the schematic drawing of the titin N2B region. (C) The putative DRAL/FHL-2-binding site alone shows proper targeting to the sarcomere, as shown in NRC double-transfected with GFP-N2B5 (a) and DRAL/FHL-2-FLAG (a'). Arrowheads in the insets point at the doublet flanking the Z-disc. (D) Coimmunoprecipitation of GFP-N2B5 and DRAL/FHL-2-FLAG. COS cells were cotransfected with GFP-N2B5 and DRAL/FHL-2-FLAG, immunprecipitation was carried out with a monoclonal anti-FLAG antibody followed by immunoblotting with a peroxidase-conjugated polyclonal rabbit anti-GFP antibody. The domain nomenclature and amino acid numbering correspond to that of the human cardiac titin sequence [X90568 (Labeit and Kolmerer, 1995)]. Bar, 10 µm.

View larger version (24K): [in a new window]   Fig. 1. Expression pattern of DRAL/FHL-2 in cardiac and skeletal muscle. (A) DRAL/FHL-2 is expressed only in cardiac muscle from adult mice. Immunoblots with a polyclonal rabbit anti-DRAL/FHL-2 antibody on whole muscle samples of adult mouse ventricle (lane 1), mouse tibialis anterior (fast twitch skeletal muscle, lane 2) and mouse soleus (slow twitch skeletal muscle, lane 3) show a band of the expected molecular weight of 34 kDa only in the heart. (B) DRAL/FHL-2 expression is upregulated in fetal mouse heart. Immunoblots with a polyclonal rabbit anti-DRAL/FHL-2 antibody on whole muscle samples of E12.5 (lane 1), E16.5 (lane 2), E18.5 (lane 3) and P0 (lane 4) heart show that DRAL/FHL-2 is expressed in cardiomyocytes during late embryonic development (upper panel). Equal amounts of heart tissue were loaded, as judged by the expression of -cardiac actin (bottom panel).

View larger version (83K): [in a new window]   Fig. 2. DRAL/FHL-2 colocalises with the N2B region of titin. (A) Schematic representation of antibody epitopes on titin. (B) Mapping of the exact position of DRAL/FHL-2 in the I-band by costaining with antibodies against different titin epitopes. Cardiac myofibrils from papillary muscle (a,b,c) or neonatal rat cardiomyocytes (d) were stained with an antibody directed against DRAL/FHL-2 (a', b', c', d'), together with antibodies directed against the N-terminus of titin (T12 epitope, a), the N2B region (I19 epitope, b), the N2A region (c) and against the PEVK region (9D10 epitope, d). DRAL/FHL-2 colocalises with the N2B region, but not with the other regions of titin. Arrowheads indicate the center of the Z-disc. Bar, 2 µm.

View larger version (127K): [in a new window]   Fig. 3. DRAL/FHL-2 interacts with the N2B region of titin in a yeast two-hybrid assay. Yeast strain L40 was cotransformed with LexA-DRAL/FHL-2 and Gal4AD-N2B (lane 1), LexA-lamin C and Gal4AD-N2B (lane 2), LexA and Gal4AD-N2B (lane 3) and LexA-DRAL/FHL-2 and Gal4AD (lane 4). Yeast transformants were streaked out on selective plates (a) and ß-galactosidase activity was detected using a filter assay (b). Results of two independent colonies per yeast transformation are shown. Only LexA-DRAL/FHL-2 in combination with Gal4AD-N2B yields any measurable ß-galactosidase activity (lane 1). N2B does not interact with an unrelated bait (LexA-lamin C, lane 2) or with LexA alone (lane 3) and LexA-DRAL/FHL-2 does not interact with Gal4AD alone (lane 4).

View larger version (49K): [in a new window]   Fig. 4. Confirmation of the interaction between DRAL/FHL-2 and the N2B and is2 regions of titin by colocalisation and pull-down experiments. (A) Transient transfection assays. GFP-N2B (a) and DRAL/FHL-2-FLAG (a') are localised in a similar pattern in transiently transfected NRC, with a broad doublet flanking the Z-disc (arrowheads) and a weaker striation at the M-band. A similar colocalisation can be observed in neonatal rat cardiomyocytes transiently transfected with GFP-is2 (b) and DRAL/FHL-2-FLAG (b'). (B) Pull-down assays: GFP-N2B and GFP-is2 interact with DRAL/FHL-2-GST but not with GST alone. Proteins in the supernatant and pellet fractions were detected by immunoblotting using a GFP antibody.

View larger version (44K): [in a new window]   Fig. 6. DRAL/FHL-2 interacts with the metabolic enzymes MM-CK, adenylate kinase and phosphofructokinase. (A) Transient transfection assays. GFP-tagged MM-CK (a), phosphofructokinase (b), and adenylate kinase (c) colocalise with DRAL/FHL-2-FLAG (a', b', c', d') in neonatal rat cardiomyocytes, with a strong signal around the Z-disc (arrowheads) and a weaker signal in the M-band (arrows). GFP-tagged Smpx/Csl (d) is also colocalised with DRAL/FHL-2. (B) Interaction of the metabolic enzymes with DRAL/FHL-2 in pull-down assays. MM-CK, adenlyate kinase and phosphofructokinase interact with DRAL/FHL-2-GST, but not with GST alone. Despite its similar localisation pattern in cardiomyocytes, Smpx/Csl does not interact with DRAL/FHL-2 in the pull-down assay. PFK, phosphofructokinase; AK1, adenylate kinase. Bar, 10 µm.

View larger version (21K): [in a new window]   Fig. 7. DRAL/FHL-2 interacts with the four and a half LIM domain protein FHL-1 but not with the LIM-only protein MLP. Pull-down assays: FLAG-tagged FHL-1 interacts with DRAL/FHL-2-GST but not with GST alone. In contrast, HA-tagged MLP shows no interaction with either GST-DRAL/FHL-2 or GST alone. The interaction of FHL-1 with DRAL/FHL-2 can be abolished by the addition of 10 mM EDTA, which unfolds LIM domains through the removal of the coordinated metal ions.

View larger version (8K): [in a new window]   Fig. 8. Schematic drawing of the N2B and is2 regions of titin and their associated proteins. DRAL/FHL-2 interacts directly with the N2B and is2 regions and serves as an adaptor molecule to couple the metabolic enzymes MM-CK, adenylate kinase and phosphofructokinase to titin. In addition, MM-CK may be bound to the M-band region of the sarcomere via its association with additional M-band proteins (not shown here). The domain nomenclature and amino acid numbering correspond to that of the human cardiac titin sequence [X90568 (Labeit and Kolmerer, 1995)].

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

Twitter